Metachromatic Leukodystrophy (MLD)
Metachromatic Leukodystrophy (MLD) is caused by a faulty ARSA gene. The current approved gene therapy, called atidarsagene autotemcel, works by inserting several healthy copies of the ARSA gene into the patient’s own cells using a lentiviral vector. The efficacy and safety of this treatment depends on the number of copies (VCN or vector copy number) added to the patient’s cells. Too low VCN may lead to insufficient correction of the deficiency and limited therapeutic effect, but too high VCN may increase the risk of adverse events. The present study describes an optimized version of the gene therapy that allows it to reach the same effect with a lower VCN when tested pre-clinically on cellular and animal models of ARSA deficiency. Researchers made several modifications to the lentiviral vector components to enhance the ARSA gene expression by 10-fold and ARSA protein activity by 4-fold compared to the original vector. If and when confirmed, this improved version of the existing treatment could alleviate gene therapy-related toxicity and reduce production costs. While encouraging for the MLD and the general gene therapy space, further studies are needed to validate the findings.